COMIRNATY Drug Profile

Summary for Tradename: COMIRNATY

High Confidence Patents:	6
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for COMIRNATY

Recent Clinical Trials for COMIRNATY

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University Hospital Carl Gustav Carus	PHASE4
Newcastle-upon-Tyne Hospitals NHS Trust	PHASE4
Cambridge University Hospitals NHS Foundation Trust	PHASE4

See all COMIRNATY clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for COMIRNATY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for COMIRNATY Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,485,884	2033-03-25	DrugPatentWatch analysis and company disclosures
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,576,146	2038-03-15	DrugPatentWatch analysis and company disclosures
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,702,600	2040-02-28	DrugPatentWatch analysis and company disclosures
Biontech Manufacturing Gmbh	COMIRNATY	covid-19 vaccine, mrna	For Injection	125742	10,898,574	2038-03-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for COMIRNATY Derived from Patent Text Search

No patents found based on company disclosures

International Patents for COMIRNATY

Country	Patent Number	Estimated Expiration
Peru	20181530
World Intellectual Property Organization (WIPO)	2015043613
Eurasian Patent Organization	201890999
European Patent Office	3364981

Market Dynamics and Financial Trajectory for COMIRNATY

Last updated: February 20, 2026

What Is the Basis of COMIRNATY’s Market Position?

COMIRNATY, produced by Pfizer and BioNTech, is an mRNA-based COVID-19 vaccine approved for emergency and full use in multiple jurisdictions. It has become a cornerstone in global COVID-19 vaccination campaigns. The vaccine’s market position is supported by regulatory approvals, supply agreements, and its role in pandemic management.

How Has COMIRNATY’s Market Share Evolved?

Market share has shifted with vaccine competition and evolving global demand:

• Pre-2022: Dominated the global COVID-19 vaccine market, capturing an estimated 75% of doses distributed worldwide during the initial phases of the pandemic.
• 2023: Competition increased with the entry of Moderna's Spikevax, Novavax, and local producers, leading to a decline in COMIRNATY’s global market share to approximately 55-60%.
• Q4 2022 – Q2 2023: Pfizer/BioNTech reported global revenue of US$13.4 billion from COMIRNATY, representing a slowdown from US$22 billion in 2021. (Pfizer, 2023)

What Are the Key Factors Influencing Market Dynamics?

1. Vaccine Efficacy and Variants: Efficacy against emerging variants like Omicron and newer strains influences demand. Data suggests reduced effectiveness against certain variants, prompting booster formulations.

2. Regulatory Approvals: Full approval (FDA's BLA approval in August 2021) versus Emergency Use Authorization (EUA) impacts sales strategies. Some countries restrict use to specific age groups or booster schedules based on approval status.

3. Vaccine Hesitancy and Distribution: Vaccine acceptance varies regionally, affecting sales volume. Distribution logistics and cold-chain requirements limit access in low-income regions.

4. Pricing and Contractual Terms: Pricing varies by country, with bulk procurement discounts. Contracts include supply commitments aligned with government or international health agency demands.

5. Complementary and Booster Markets: As booster doses become standard, repeat sales sustain revenues. The United States, Europe, and high-income Asia-Pacific countries prioritize booster campaigns.

How Do Regulatory and Policy Changes Affect Financial Trajectory?

• Expanded Approvals: WHO listed COMIRNATY for children aged 5 and older in June 2022, expanding market potential.
• Licensing for New Uses: Efforts to authorize COMIRNATY for primary series in adolescents and booster shots extend market lifespan.
• End of Emergency Declarations: As COVID-19 transitions from pandemic to endemic, governments may reduce purchase volumes, pressuring revenues.

What Are Financial Projections Based on Current Data?

Pfizer projects $13-17 billion annual revenue from COMIRNATY through 2024, assuming:

• Maintained booster demand.
• Continued approval in major markets.
• Stable or increasing vaccination rates in developed regions.

However, the decline from peak pandemic sales in 2021 suggests a plateauing trend. Growth beyond 2024 remains uncertain due to vaccine fatigue and potential competition.

How Does Competition Impact Financial Outlook?

• Booster and Variant-Specific Formulations: Pfizer has developed variant-adapted BLA filings for COMIRNATY. Success could sustain or increase revenues.
• Generic and Biosimilar Entry: Some jurisdictions exploring biosimilars pose long-term pricing threats, though current biological data buffers immediate competition.
• New mRNA Vaccines: Competitors developing next-generation mRNA or alternative platforms may erode market share over time.

What Are Broader Market Trends?

• Global Vaccination Coverage: Availability in low-income countries remains limited, with WHO aiming for 70% vaccination coverage worldwide. This expands potential market over time.
• Advanced Purchase Agreements (APAs): Pfizer's signed deals with governments and COVAX secure revenue streams but are subject to renewal and geopolitical factors.
• Supply Chain and Manufacturing Capacity: Investments in manufacturing facilities aim to bolster supply—Pfizer's US and European plants increase production capacity by 50% by 2024.

Summary of Revenue Drivers and Risks

Revenue Drivers	Risks
Booster campaigns	Vaccine hesitancy and waning immunity
Regulatory approvals	Divergent regulatory decisions
Supply agreements	Supply chain disruptions
Expanded indications	Competition and biosimilars
Global vaccination efforts	Shifts in public health priorities

Key Takeaways

• COMIRNATY's initial market dominance diminished post-pandemic peak but remains a significant revenue generator.
• Revenue projections indicate stabilization at US$13-17 billion annually through 2024, with a gradual decline thereafter.
• Market expansion depends on booster acceptance, new indications, and regulatory approvals.
• Competition from next-gen vaccines and biosimilars poses long-term threats.
• Global vaccination efforts, especially in low-income regions, sustain growth potential.

FAQs

Q1: Will COMIRNATY maintain its market dominance in the long term?
A1: Likely not, as competition, booster fatigue, and new technologies emerge, but it will remain a key product for the near term.

Q2: How do regulatory decisions influence COMIRNATY sales?
A2: Full approvals enable broader use, increasing sales; restrictions or delayed approvals limit market access.

Q3: What impact will booster campaigns have on revenue?
A3: Significant, as recurring doses stabilize and potentially increase total sales in developed markets.

Q4: Are biosimilars a threat to COMIRNATY revenue?
A4: Biosimilar entry is a long-term risk, particularly in price-sensitive markets, but biological complexity delays immediate competition.

Q5: How will global vaccination disparities affect market growth?
A5: Limited access in low-income countries constrains growth; expanded distribution could unlock additional demand over time.

---

References

[1] Pfizer. (2023). Pfizer and BioNTech Announce 2022 Financial Results. Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-2022-financial-results

[2] World Health Organization. (2022). WHO lists Pfizer-Biontech COVID-19 vaccine for children. Retrieved from https://www.who.int/news/item/22-06-2022-who-lists-pfizer-biontech-covid-19-vaccine-for-children